West Pharmaceutical Services (WST) Stock Price, Quote & News

Company Profile

West Pharmaceutical Services, Inc. designs, manufactures, and sells containment and delivery systems for injectable drugs and healthcare products in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. It operates in two segments, Proprietary Products and Contract-Manufactured Products. The Proprietary Products segment offers stoppers and seals for injectable packaging systems; syringe and cartridge components, including custom solutions for the needs of injectable drug applicati...

Industry: Medical Instruments & Supplies

Sector: Healthcare

Phone: 610 594 2900

Website: www.westpharma.com

Address:

530 Herman O. West Drive, Exton, United States

nikitatrades Oct. 25 at 6:59 PM

$WST - Beats, Raises, and Reassures The Headline: Strong Q3 beat followed by a guidance raise. The Numbers: EPS: $1.96 (Beat by 16%) Revenue: $804.6M (Beat) Key Takeaway: Raised full-year sales and profit guidance. A confident signal of operational stability and growth.

0 · Reply

IN0V8 Oct. 24 at 7:52 PM

$WST Buy Deutsche Bank raises PT to $345 from $305

0 · Reply

JarvisFlow Oct. 24 at 3:06 PM

UBS has adjusted their stance on West Pharmaceutical Servs ( $WST ), setting the rating to Buy with a target price of 320 → 355.

0 · Reply

JarvisFlow Oct. 24 at 12:34 PM

Keybanc updates rating for West Pharmaceutical Servs ( $WST ) to Overweight, target set at 325 → 350.

0 · Reply

SuperGreenToday Oct. 23 at 9:26 PM

$WST

0 · Reply

StocktwitsNews Oct. 23 at 6:48 PM

WST Stock Soars After Company Raises Full-Year Guidance On Strong Demand For GLP-1 Drug Components $WST $AVUS $XRMI https://stocktwits.com/news/equity/markets/wst-stock-soars-after-company-raises-full-year-guidance-on-strong-demand-for-glp-1-drug-components/cLG4YS9R3ro

0 · Reply

JarvisFlow Oct. 23 at 5:54 PM

Evercore ISI Group has updated their rating for West Pharmaceutical Servs ( $WST ) to Outperform with a price target of 390.

0 · Reply

notreload_ai Oct. 23 at 5:12 PM

$WST raises its 2025 outlook after strong demand for self-injection devices drives revenue and profit above expectations. https://notreload.xyz/west-pharmaceuticals-raises-2025-outlook-as-self-injection-device-sales-surge/

0 · Reply

ZacksResearch Oct. 23 at 4:59 PM

$WST surprise Q3 earnings beat — with a 17.4% EPS estimate beat and revenues up 7.7% year over year, driven by Proprietary Products and Contract-Manufactured Products. 📈 Yet, the stock has lagged the industry and S&P 500's gains this year. Opportunity assessment here 👉 https://www.zacks.com/stock/news/2775686/wst-stock-up-on-q3-earnings-beat-eps-view-raised-on-demand-fx-benefit?cid=sm-stocktwits-2-2775686-body-17343&ADID=SYND_STOCKTWITS_TWEET_2_2775686_BODY_17343

0 · Reply

ZacksResearch Oct. 23 at 3:59 PM

$WST just crushed Q3 — and raised its EPS outlook 🚀 Strong demand, FX tailwinds, and solid growth in Proprietary Products powered the beat, signaling momentum heading into year-end. Full breakdown of the bullish setup here 👉 https://www.zacks.com/stock/news/2775686/wst-stock-up-on-q3-earnings-beat-eps-view-raised-on-demand-fx-benefit?cid=sm-stocktwits-2-2775686-teaser-17341&ADID=SYND_STOCKTWITS_TWEET_2_2775686_TEASER_17341

0 · Reply

West to Participate in Upcoming Investor Conferences

Oct 23, 2025, 3:07 PM EDT - 2 days ago

West Pharmaceutical Services, Inc. (WST) Q3 2025 Earnings Call Transcript

Oct 23, 2025, 12:16 PM EDT - 2 days ago

West Pharma Soars After Q3 Beat, Lifts Outlook On GLP-1 Demand

Oct 23, 2025, 6:52 AM EDT - 2 days ago

West Pharma boosts annual profit forecast on strong demand for its drug components

Oct 23, 2025, 6:00 AM EDT - 2 days ago

West Reports Third-Quarter 2025 Results

Oct 21, 2025, 5:57 AM EDT - 4 days ago

West Pharmaceutical Services: HVP Moat Cum GLP-1 And Biologics Tailwinds Reinforce Upward Momentum

Oct 9, 2025, 6:00 AM EDT - 16 days ago

West to Host Third-Quarter 2025 Conference Call

Oct 3, 2025, 10:46 AM EDT - 22 days ago

Top 50 High-Quality Dividend Growth Stocks For October 2025

AAPL ACN ALLE AMAT APH CTAS DHI

Oct 1, 2025, 10:58 PM EDT - 23 days ago

Top 15 High-Growth Dividend Stocks For October 2025

ACN DPZ EOG FDX INTU MSCI NDSN

Sep 24, 2025, 3:27 PM EDT - 4 weeks ago

West Pharmaceutical Services, Inc. (WST) Presents at Bank of America Global Healthcare Conference 2025 Transcript

Sep 6, 2025, 12:18 PM EDT - 7 weeks ago

Top 50 High-Quality Dividend Stocks For September 2025

AAPL ACN ALLE AMAT APH CTAS DHI

Sep 3, 2025, 5:11 PM EDT - 7 weeks ago

West Pharmaceutical Services, Inc. (WST) Presents At Wells Fargo 2025 Healthcare Conference (Transcript)

Aug 27, 2025, 2:09 PM EDT - 2 months ago

Best Dividend Aristocrats For September 2025

ABBV ABT ADM ADP AFL ALB AMCR

Aug 21, 2025, 6:00 AM EDT - 2 months ago

West to Participate in Upcoming Investor Conferences in September 2025

Aug 6, 2025, 11:50 AM EDT - 2 months ago

Top 50 High-Quality Dividend Stocks For August 2025

AAPL ACN ALLE AMAT APH CTAS DHI

Jul 30, 2025, 12:20 PM EDT - 3 months ago

West Pharmaceutical: Q2 Earnings Suggest Recovery

Jul 27, 2025, 1:52 AM EDT - 3 months ago

West Pharmaceutical Services: Low Debt, High Profit, And A Waning Destocking Problem

Jul 24, 2025, 1:58 PM EDT - 3 months ago

West Pharmaceutical Services, Inc. (WST) Q2 2025 Earnings Call Transcript

Jul 24, 2025, 10:38 AM EDT - 3 months ago

West Pharma Lifts Outlook On Surging GLP-1 Demand, Stock Soars

Jul 24, 2025, 8:02 AM EDT - 3 months ago

West Pharma raises annual profit forecast on strong demand for its drug components

Jul 24, 2025, 6:00 AM EDT - 3 months ago

West Announces Second-Quarter 2025 Results and Fourth-Quarter 2025 Dividend, Updates Full-Year 2025 Guidance

Jul 21, 2025, 6:00 AM EDT - 3 months ago

West Welcomes Robert McMahon as Incoming Chief Financial Officer

Jul 8, 2025, 6:00 AM EDT - 3 months ago

West to Host Second-Quarter 2025 Conference Call

Jul 7, 2025, 2:23 AM EDT - 3 months ago

WST Shareholders Have the Right to Lead the West Pharmaceutical Services, Inc. Securities Lawsuit - Contact the DJS Law Group to Discuss Your Rights - WST

Jul 6, 2025, 8:25 AM EDT - 3 months ago

SHAREHOLDER REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of West Pharmaceutical Services

Jul 3, 2025, 8:15 AM EDT - 4 months ago

SHAREHOLDER NOTICE: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of West Pharmaceutical Services

Jun 24, 2025, 11:04 AM EDT - 4 months ago

INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of West Pharmaceutical Services

Jun 19, 2025, 4:24 AM EDT - 4 months ago

The Gross Law Firm Reminds Shareholders of a Lead Plaintiff Deadline of July 7, 2025 in West Pharmaceutical Services, Inc. Lawsuit – WST

Jun 9, 2025, 5:45 AM EDT - 4 months ago

The Gross Law Firm Reminds Shareholders of a Lead Plaintiff Deadline of July 7, 2025 in West Pharmaceutical Services, Inc. Lawsuit - WST

nikitatrades Oct. 25 at 6:59 PM

0 · Reply

IN0V8 Oct. 24 at 7:52 PM

$WST Buy Deutsche Bank raises PT to $345 from $305

0 · Reply

JarvisFlow Oct. 24 at 3:06 PM

UBS has adjusted their stance on West Pharmaceutical Servs ( $WST ), setting the rating to Buy with a target price of 320 → 355.

0 · Reply

JarvisFlow Oct. 24 at 12:34 PM

Keybanc updates rating for West Pharmaceutical Servs ( $WST ) to Overweight, target set at 325 → 350.

0 · Reply

SuperGreenToday Oct. 23 at 9:26 PM

$WST

0 · Reply

StocktwitsNews Oct. 23 at 6:48 PM

0 · Reply

JarvisFlow Oct. 23 at 5:54 PM

Evercore ISI Group has updated their rating for West Pharmaceutical Servs ( $WST ) to Outperform with a price target of 390.

0 · Reply

notreload_ai Oct. 23 at 5:12 PM

0 · Reply

ZacksResearch Oct. 23 at 4:59 PM

0 · Reply

ZacksResearch Oct. 23 at 3:59 PM

0 · Reply

theoptionsplug Oct. 23 at 2:38 PM

Best performers in the S&P so far this morning $LVS $WST $DOW $MPWR

0 · Reply

DonCorleone77 Oct. 23 at 12:20 PM

$WST West Pharmaceutical reports Q3 adjusted EPS $1.96, consensus $1.69 -- Q3 revenue $804.6M, consensus $787.7M. -- Ups FY25 adjusted EPS view to $7.06-$7.11 from $6.65-$6.85, consensus $6.78. -- Raises FY25 revenue view to $3.06B-$3.07B from $3.04B-$3.06B, consensus $3.05B. -- Backs FY25 capital spending view $275M.

0 · Reply

Estimize Oct. 23 at 10:03 AM

$WST reported - EPS and - revenue for Q3. http://www.estimize.com/intro/wst?chart=historical&metric_name=eps&utm_content=WST&utm_medium=act

0 · Reply

MoneyGroupLLC Oct. 21 at 11:51 AM

Enter: $WST NOV 21 2025 $280 CALLS Buy in Price: $14.80 - $15.54 Take Profit: $34.34 Stop Bleeding: $13.02 ROI Potential: 132% Exit Within: 3 Weeks https://moneygroup.us/alerts

0 · Reply

SuperGreenToday Oct. 20 at 9:18 PM

$WST

0 · Reply

MoneyGroupLLC Oct. 20 at 1:51 PM

Enter: $WST NOV 21 2025 $280 CALLS Buy in Price: $12.80 - $14.60 Take Profit: $24.06 Stop Bleeding: $11.26 ROI Potential: 88% Exit Within: 2 Weeks https://moneygroup.us/alerts

0 · Reply

ZacksResearch Oct. 17 at 2:29 PM

Can $WST maintain its earnings surprise streak? 🔍 WST has beaten earnings estimates in the last four quarters, with an average surprise of 16.81%. For Q3, organic revenue is expected to grow 2.5% to 3.5%, but EPS is projected to decline 9.7% YoY. Full Q3 preview here 👉 https://www.zacks.com/stock/news/2770951/wst-q3-earnings-preview-can-glp-1-momentum-outweigh-margin-pressure?cid=sm-stocktwits-2-2770951-body-16565&ADID=SYND_STOCKTWITS_TWEET_2_2770951_BODY_16565

0 · Reply

ZacksResearch Oct. 17 at 1:29 PM

$WST Q3 preview — bullish demand, bearish margins? Strong GLP-1 and biologics demand could lift revenue, but labor issues, tariffs, and plant shutdowns are pressing on margins. The big question: can growth outmuscle the cost squeeze? Full earnings setup here 👉 https://www.zacks.com/stock/news/2770951/wst-q3-earnings-preview-can-glp-1-momentum-outweigh-margin-pressure?cid=sm-stocktwits-2-2770951-teaser-16564&ADID=SYND_STOCKTWITS_TWEET_2_2770951_TEASER_16564

0 · Reply

MoneyGroupLLC Oct. 17 at 1:41 AM

Enter: $WST NOV 21 2025 $270 CALLS Buy in Price: $15.64 - $16.50 Take Profit: $36.28 Stop Bleeding: $13.76 ROI Potential: 132% Exit Within: 3 Weeks https://moneygroup.us/alerts

0 · Reply

ZacksResearch Oct. 15 at 12:28 PM

Is $WST a buy amid GLP-1 boom? 🤔 Despite a 20.3% drop so far this year, West Pharmaceutical is riding high on GLP-1 demand and high-value product momentum, with earnings expected to grow 8.4% over the next five years 📈. However, tariff risks and operational challenges could temper growth. Dive into the details here 👉 https://www.zacks.com/stock/news/2768974/reasons-to-retain-west-pharmaceutical-stock-in-your-portfolio-for-now?cid=sm-stocktwits-2-2768974-body-16096&ADID=SYND_STOCKTWITS_TWEET_2_2768974_BODY_16096

0 · Reply

ZacksResearch Oct. 15 at 11:28 AM

$WST — Still worth holding? Here’s why the story’s not over yet. GLP-1 demand and high-value products are driving solid growth potential for West Pharmaceutical, even as tariffs and execution risks pressure margins. See why the long-term case still holds 👉 https://www.zacks.com/stock/news/2768974/reasons-to-retain-west-pharmaceutical-stock-in-your-portfolio-for-now?cid=sm-stocktwits-2-2768974-teaser-16095&ADID=SYND_STOCKTWITS_TWEET_2_2768974_TEASER_16095

0 · Reply

MoneyGroupLLC Oct. 12 at 5:56 PM

Enter: $WST NOV 21 2025 $270 CALLS Buy in Price: $11.60 - $16.50 Take Profit: $23.90 Stop Bleeding: $10.21 ROI Potential: 106% Exit Within: 199 Minutes https://moneygroup.us/alerts

0 · Reply

Market Cap	22.09B
Revenue (ttm)	2.89B
Net Income (ttm)	492.70M
EPS (ttm)	N/A
PE Ratio	39.80
Forward PE	41.13
Profit Margin	17.03%
Debt to Equity Ratio	0.07

Volume	819,400
Avg Vol	650,414
Day's Range	N/A - N/A
Shares Out	71.91M
Stochastic %K	60%
Beta	1.07
Analysts	Strong Sell
Price Target	$323.42